As president, Karen oversees Evidera’s global team, providing strategic direction for the organization in this rapidly changing health care environment. Before joining Evidera, Karen was senior vice president and global head of Early Development for PPD, overseeing PPD’s clinical pharmacology units, early development site network, and early development-focused operations staff. Prior to that, Karen served as vice president and global head of PPD® Consulting, leading regulatory and product development consulting across all major therapeutic areas and provided strategic direction for consulting in key practice areas such as biosimilars, adaptive trial design, rare diseases, and pediatrics.
Before joining PPD in 2009, Karen was senior director in oncology clinical development at MedImmune/AstraZeneca. There, she led product development teams for several biologics compounds, including monoclonal antibodies, bispecific antibodies, and antibody conjugates. Earlier in her career, she was a staff pediatric oncologist and senior investigator at Children’s National Medical Center in Washington, D.C., where she established the institution’s first hematopoietic stem cell transplantation laboratory, served as an attending physician in oncology, and conducted NIH-funded research in signal transduction in human neuroectodermal tumors.
Karen received her medical degree from The Ohio State University followed by a pediatric residency at the same institution. She completed fellowships in pediatric hematology/oncology and transfusion medicine at Children’s National Medical Center and The Cleveland Clinic, respectively. She holds an active license to practice medicine in the District of Columbia.